opportunities in multi-medication patients. Maricann and the Counterparty will work together to assist patients in achieving their desired therapeutic goals while always keeping their safety paramount.
CCIM: Does MARI have any intent to enter the Hemp market either directly through acquisitions or through joint ventures and partnerships?
MARI: Planned cultivation operations at the Ebersbach facility (West of Dresden) includes an outdoor hemp farm from which Maricann will derive high CBD content active pharmaceutical ingredients.
CCIM: Thank you so much for your time. Is there an email or link our readers can learn more? Will an updated corporate presentation (investors’ deck) MARI available?
MARI: Yes, your readers can visit our web site at maricann.ca and email inquiries to: [email protected]
The Ebersbach facility
239